The news: Prediction market exchange Kalshi is expanding beyond sports betting into biotech by allowing users to bet on clinical trials and FDA approvals. The pilot program with technology partner AppliedXL will focus on phase 3 clinical trial outcomes and upcoming FDA approval decisions involving large pharma companies. The questions users can bet on include specific upcoming FDA approvals from Sanofi and Gilead Sciences, such as “Will the FDA approve Sanofi’s oral therapy for Gaucher disease?”

Why it matters: The platform creates a new publicly visible market signal about expected clinical trial outcomes. If the market gains traction, its odds could become another data point for investors and potential acquirers evaluating biotech companies. Critics of Kalshi are concerned the market could create incentives for employees or researchers to trade on insider information, per Bloomberg. Kalshi says it will use an employment verification system to screen out traders who work at those companies.

Implications for biotech and pharma companies: For smaller biotechs that depend on licensing deals or acquisitions, pessimistic market odds could weaken negotiating leverage, while favorable odds could support fundraising and valuations.

Prediction markets could also add another layer of public scrutiny around clinical trials, forcing companies to address changing market sentiment even before official results are released. Meanwhile, low market odds could discourage some potential patients from enrolling in clinical trials, creating another recruiting challenge for studies that are already difficult to fill.

The market is still too new to know whether its prices will become meaningful signals or remain a niche product. Its influence will largely depend on whether institutional investors, biotech executives, and the financial media begin treating its odds as credible indicators of clinical trial outcomes.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.